scPharmaceuticals’ (SCPH) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of scPharmaceuticals (NASDAQ:SCPH) in a research report report published on Monday,Benzinga reports. They currently have a $18.00 price target on the stock. HC Wainwright also issued estimates for scPharmaceuticals’ FY2029 earnings at $0.70 EPS.

Separately, Craig Hallum cut their target price on shares of scPharmaceuticals from $16.00 to $12.00 and set a “buy” rating for the company in a research note on Thursday, November 14th.

scPharmaceuticals Stock Performance

NASDAQ:SCPH opened at $3.18 on Monday. scPharmaceuticals has a 1 year low of $3.08 and a 1 year high of $6.20. The firm has a 50 day moving average of $3.39 and a 200-day moving average of $3.96. The company has a current ratio of 8.08, a quick ratio of 6.89 and a debt-to-equity ratio of 1.66. The stock has a market capitalization of $159.13 million, a P/E ratio of -1.67 and a beta of 0.11.

Institutional Trading of scPharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of SCPH. BNP Paribas Financial Markets increased its holdings in shares of scPharmaceuticals by 116.9% in the third quarter. BNP Paribas Financial Markets now owns 5,753 shares of the company’s stock valued at $26,000 after purchasing an additional 3,101 shares in the last quarter. Legato Capital Management LLC acquired a new stake in shares of scPharmaceuticals in the fourth quarter valued at approximately $37,000. China Universal Asset Management Co. Ltd. acquired a new stake in shares of scPharmaceuticals in the fourth quarter valued at approximately $38,000. Virtu Financial LLC acquired a new stake in shares of scPharmaceuticals in the third quarter valued at approximately $46,000. Finally, ProShare Advisors LLC acquired a new stake in shares of scPharmaceuticals in the fourth quarter valued at approximately $48,000. Institutional investors and hedge funds own 89.52% of the company’s stock.

About scPharmaceuticals

scPharmaceuticals Inc, a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX.